Lilly's Sale Of Diabetes Drug To Amphastar Could Exceed $1B
Indiana-based pharmaceutical company Eli Lilly and Co. has agreed to sell its Baqsimi low blood sugar medication to Amphastar for a price that could exceed $1 billion, the companies said Monday....To view the full article, register now.
Already a subscriber? Click here to view full article